The reasons for patients not receiving second line treatment in both cohorts was either death from cancer and/or it not being safe to deliver further systemic therapy due to clinical deterioration secondary to cancer (except for one patient in the CDK4/6i cohort who died from drug-induced pneumonitis). The gene discussed is CDK4; the disease is pneumonitis.